IRIS
CIPRIANI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.319
AS - Asia 7.371
EU - Europa 6.895
SA - Sud America 761
AF - Africa 109
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 18
Totale 28.499
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.125
SG - Singapore 3.302
IE - Irlanda 1.630
RU - Federazione Russa 1.526
CN - Cina 1.501
HK - Hong Kong 755
IT - Italia 734
TR - Turchia 720
BR - Brasile 650
VN - Vietnam 624
SE - Svezia 613
DE - Germania 599
UA - Ucraina 407
GB - Regno Unito 394
FR - Francia 351
FI - Finlandia 239
NL - Olanda 156
IN - India 124
CA - Canada 117
JP - Giappone 80
BD - Bangladesh 57
BE - Belgio 46
ZA - Sudafrica 43
AR - Argentina 40
MX - Messico 40
ES - Italia 36
PL - Polonia 33
LT - Lituania 29
ID - Indonesia 23
CZ - Repubblica Ceca 22
IQ - Iraq 20
PK - Pakistan 19
AU - Australia 17
EC - Ecuador 17
VE - Venezuela 16
KR - Corea 15
MA - Marocco 15
AT - Austria 14
EU - Europa 14
SA - Arabia Saudita 14
JO - Giordania 13
CO - Colombia 12
DZ - Algeria 10
GR - Grecia 10
JM - Giamaica 10
PH - Filippine 10
TN - Tunisia 10
UZ - Uzbekistan 10
MY - Malesia 9
NP - Nepal 8
PY - Paraguay 8
AL - Albania 7
AZ - Azerbaigian 7
CH - Svizzera 7
EG - Egitto 7
IL - Israele 7
KZ - Kazakistan 7
NZ - Nuova Zelanda 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
MK - Macedonia 6
RO - Romania 6
TH - Thailandia 6
BO - Bolivia 5
KE - Kenya 5
LB - Libano 5
PE - Perù 5
TW - Taiwan 5
DK - Danimarca 4
DO - Repubblica Dominicana 4
HU - Ungheria 4
NI - Nicaragua 4
PT - Portogallo 4
CI - Costa d'Avorio 3
CR - Costa Rica 3
GE - Georgia 3
GT - Guatemala 3
HN - Honduras 3
IR - Iran 3
KW - Kuwait 3
LU - Lussemburgo 3
MM - Myanmar 3
PS - Palestinian Territory 3
RS - Serbia 3
SN - Senegal 3
TT - Trinidad e Tobago 3
AO - Angola 2
BB - Barbados 2
BG - Bulgaria 2
CW - ???statistics.table.value.countryCode.CW??? 2
ET - Etiopia 2
HR - Croazia 2
KG - Kirghizistan 2
LV - Lettonia 2
NG - Nigeria 2
NO - Norvegia 2
UY - Uruguay 2
YT - Mayotte 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AG - Antigua e Barbuda 1
Totale 28.476
Salva come PNG Salva come JPEG
Città #
Singapore 1.781
Jacksonville 1.642
Dublin 1.624
Chandler 1.609
San Jose 1.414
Dallas 1.196
Ashburn 818
Hong Kong 744
Santa Clara 661
Boardman 579
Council Bluffs 448
Izmir 404
New York 340
The Dalles 335
Moscow 294
Nanjing 273
Wilmington 246
Lawrence 235
Princeton 235
Beijing 230
San Mateo 225
Ho Chi Minh City 201
Ann Arbor 196
Los Angeles 160
Lauterbourg 152
L'aquila 129
Hanoi 128
Amsterdam 120
Milan 107
Nanchang 100
Hefei 89
Dearborn 85
Woodbridge 85
Munich 81
Seattle 77
Tokyo 73
São Paulo 70
Shenyang 65
Helsinki 57
Des Moines 56
Shanghai 51
Verona 51
L’Aquila 48
Orem 48
Frankfurt am Main 47
Kunming 46
Columbus 45
Mountain View 43
Brussels 42
Hebei 42
Jiaxing 41
Rome 39
Jinan 35
Dong Ket 34
Montreal 33
Tianjin 33
Changsha 31
Chicago 31
Johannesburg 31
Houston 30
Lappeenranta 30
Phoenix 30
Stockholm 29
Zhengzhou 29
Brooklyn 27
Haiphong 27
Norwalk 27
Philadelphia 27
Chennai 25
Pune 25
Warsaw 25
Da Nang 24
San Francisco 23
Denver 22
London 22
Hangzhou 21
Manchester 21
Pescara 21
Atlanta 20
New Delhi 20
Guangzhou 19
Rio de Janeiro 19
Brno 18
Ningbo 18
Ankara 17
Falkenstein 17
Toronto 17
Assago 16
Belo Horizonte 16
Boston 15
Kitzingen 15
Brasília 14
Mexico City 14
Amman 13
Mumbai 13
Nuremberg 13
Poplar 13
Charlotte 12
Jakarta 12
Guarulhos 11
Totale 18.962
Salva come PNG Salva come JPEG
Nome #
Studio dell’espressione della chemochina SDF-1 e del suo recettore CXCR4 nella cute e nelle cellule endoteliali microvascolari di pazienti affetti da sclerosi sistemica (SSc). 203
Aumento dei linfociti circolanti gamma-delta Vdelta1+ in corso di malattie infiammatorie intestinali 182
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis 181
Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis 174
FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome 159
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 159
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 158
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 157
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 156
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. 154
Evaluating the multivisceral involvement on adult-onset Still’s disease to retrieve imaging-based differences in patients with and without macrophage activation syndrome: results from a single-centre observational study 154
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 153
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 151
Prognostic factors of adult onset Still’s disease: analysis of 100 cases in 3 tertiary referral centers 151
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 150
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 148
Linfociti T Gamma-Delta (G/D) in pazienti con malattie infiammatorie intestinali (IBD) 143
Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis 143
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 143
PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis 142
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations 141
Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. 138
association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome. 138
Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort 136
Cardiovascular disease in primary sjögren’s syndrome 136
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 136
Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? 136
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 135
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 133
T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. 133
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 132
Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences 131
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis 130
Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18. 130
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 130
Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease 128
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 128
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. 127
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 126
Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6 125
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 125
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 125
Stem cell therapies for systemic sclerosis 124
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 124
Dissecting the clinical heterogeneity of adult-onset Still's disease, results from a multi-dimensional characterisation and stratification 124
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 123
Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis 123
Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization 122
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 122
Endothelial progenitor cells: Are they displaying a function in autoimmune disorders? 122
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. 121
Comment on 'Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?' 120
SDF-1/CXCR4 system in microvascular endothelial cells and skin from patients affected by systemic sclerosi 120
Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review) 120
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling 120
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 120
Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis 119
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 119
GAMMA/DELTA T CELL APOPTOSIS IN SYSTEMIC SCLEROSIS PATIENTS 118
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 118
Combined approach to the initial stage raynaud’s phenomenon diagnosis by means of dynamic digital telehermograpy, capillaroscopy and pletismography. Preliminary findings. 117
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies a very early cardiac involvement in systemic sclerosis patients of recent onset 117
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 117
Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort 117
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 117
Parenchymal lung disease in adult onset Still's disease: An emergent marker of disease severity - Characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients 117
Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander? 117
Gamma-delta T cells are not involved in the natural and antibody-dependent cytotoxicity of peripheral blood mononuclear cells in inflammatory bowel disease. 117
Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease 116
Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms 116
Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. 116
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 116
 T cells in placenta and skin: their different functions may support the paradigm of microchimerism in systemic sclerosi 115
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 115
Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 114
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. 114
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. 114
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. 114
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. 114
DUO Registry Group. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. 113
Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis 113
Variations of neuronal nitric oxide synthase in systemic sclerosis skin 111
EFFICACY AND SAFETY OF RITUXIMAB TREATMENT IN EARLY PRIMARY SJOGREN'S SYNDROME: A CLINICAL, HISTOLOGICAL AND MOLECULAR STUDY 111
Interleukin-9 and T helper type 9 cells in rheumatic diseases 111
Interstitial lung disease in systemic sclerosis: current and future treatment. 111
Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis 110
Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study 110
Response to: ‘Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al’ by Chen et al 110
Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. 110
Long-term Safety of Rituximab in Primary Sjögren Syndrome: The Experience of a Single Center 109
Is minor salivary gland biopsy more than a diagnostic tool in primary Sjo¨gren׳s syndrome? Association between clinical, histopathological, and molecular features: A retrospective study 109
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. 109
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study 109
IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study 109
EFFICACY AND SAFETY OF RITUXIMAB ORIGINATOR AND BIOSIMILAR IN PRIMARY SJOGREN'S SYNDROME IN A REAL-LIFE SETTING 109
The assessment of atlantoaxial joint involvement in patients with rheumatoid arthritis, results from an observational "real-life" study 108
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 108
Increase of circulating gamma/delta T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease 108
CARDIAC MAGNETIC RESONANCE IMAGING WITH PHARMACOLOGICAL STRESS PERFUSION IN ASYMPTOMATIC PATIENTS WITH SYSTEMIC SCLEROSIS 108
The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis 108
Totale 12.743
Salva come PNG Salva come JPEG
Categoria #
all - tutte 126.634
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 126.634
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021104 0 0 0 0 0 0 0 0 0 0 0 104
2021/20221.310 74 88 249 96 33 19 28 63 108 68 93 391
2022/20234.607 336 251 82 479 395 489 31 298 2.013 30 143 60
2023/20241.248 168 74 82 157 106 363 25 73 9 57 36 98
2024/20255.119 114 89 484 180 650 461 673 394 1.179 213 346 336
2025/202610.239 535 1.005 748 1.149 942 740 1.757 413 1.022 1.130 673 125
Totale 28.846